The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities
М. V. Maevskaya(Sechenov University), Минара Шамхаловна Шамхалова, Kh. B. Kodzoeva(Sechenov University), В. В. Бредер, N. V. Korochanskaya(Kuban State Medical University), В. Л. Дощицин(Pirogov Russian National Research Medical University), М. В. Шестакова, Nana Pogosova(National Medical Research Center of Cardiology), Alexander Yur'evich Mayorov, K. A. Komshilova(Endocrinology Research Center), Natalia Geyvandova, Ekaterina Е. Mishina(Endocrinology Research Center), Е. А. Трошина, В. Т. Ивашкин(Institute of Electronic Measurements KVARZ (Russia)), Е. N. Dudinskaya(Pirogov Russian National Research Medical University), О. Н. Ткачева, Е. В. Ершова, И. Г. Никитин(Pirogov Russian National Research Medical University), А. И. Тарзиманова(Sechenov University), M. Yu. Nadinskaya(Sechenov University), Yu. V. Kotovskaya
Cited by 59
Related Papers
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
|The Lancet|2023|676
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
|Journal of Clinical Oncology|2022|398
The Concept of Folic Acid in Health and Disease
|Molecules|2021|284